| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
LY 206130 targets the serotonin 5-HT1A receptor as a selective antagonist. 5-HT1A is a Gi/o-coupled GPCR that inhibits adenylyl cyclase and reduces cAMP when activated by serotonin. By blocking this receptor, LY 206130 prevents serotonin-mediated inhibition of serotonergic and dopaminergic neurons. This leads to increased norepinephrine and dopamine release. Its selectivity for 5-HT1A over other 5-HT receptor subtypes underlies its pharmacological profile.
|
|---|---|
| ln Vitro |
In vitro, LY 206130 selectively antagonizes the 5-HT1A receptor with high affinity. It blocks 5-HT1A-mediated signaling (e.g., cAMP inhibition) in cells expressing recombinant 5-HT1A receptors. In rat brain membrane preparations, it competitively inhibits [3H]-8-OH-DPAT binding to 5-HT1A receptors. It demonstrates selectivity over other 5-HT receptor subtypes and neurotransmitter transporters.
|
| ln Vivo |
In vivo, LY 206130 (3.0 mg/kg, s.c.) significantly increases norepinephrine levels by 60% and dopamine levels by 34% without affecting 5-HT levels in rat brain microdialysis studies. It modulates serotonergic neurotransmission and demonstrates potential antidepressant-like and anxiolytic-like effects in animal behavioral models. It shows favorable brain penetration and is used to study 5-HT1A receptor function in vivo.
|
| Enzyme Assay |
For 5-HT1A receptor binding assays, membrane fractions from rat brain or cells expressing recombinant 5-HT1A receptors are incubated with [3H]-8-OH-DPAT in binding buffer. Serial dilutions of LY 206130 are added, and reactions proceed for 60–90 min at 25°C. Bound radioactivity is measured by scintillation counting. Ki values are calculated using the Cheng-Prusoff equation.
|
| Cell Assay |
For functional cAMP assays, cells expressing 5-HT1A receptors are treated with forskolin and 5-HT in the presence of LY 206130. cAMP levels are measured by HTRF or ELISA. For neurotransmitter release assays, rat brain slices are incubated with LY 206130, and norepinephrine, dopamine, and serotonin levels in the perfusate are measured by HPLC with electrochemical detection.
|
| Animal Protocol |
For in vivo microdialysis studies, rats are implanted with guide cannulae in the medial prefrontal cortex or hippocampus. After recovery, microdialysis probes are inserted, and LY 206130 (3.0 mg/kg, s.c.) is administered. Dialysate samples are collected at 20-min intervals and analyzed for norepinephrine, dopamine, and serotonin by HPLC-ECD.
|
| References |
| Molecular Formula |
C17H24N2O2
|
|---|---|
| Molecular Weight |
288.39
|
| Exact Mass |
288.184
|
| CAS # |
127414-58-8
|
| PubChem CID |
124433
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.17g/cm3
|
| Boiling Point |
521.5ºC at 760 mmHg
|
| Flash Point |
269.2ºC
|
| Vapour Pressure |
1.06E-11mmHg at 25°C
|
| Index of Refraction |
1.608
|
| LogP |
3.22
|
| tPSA |
57.28
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
21
|
| Complexity |
307
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC(COC1=CC=CC2NC=CC1=2)CNC1CCCCC1
|
| InChi Key |
PITGAFMHSKTZOO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H24N2O2/c20-14(11-19-13-5-2-1-3-6-13)12-21-17-8-4-7-16-15(17)9-10-18-16/h4,7-10,13-14,18-20H,1-3,5-6,11-12H2
|
| Chemical Name |
1-(cyclohexylamino)-3-(1H-indol-4-yloxy)propan-2-ol
|
| Synonyms |
LY206130; LY-206130; LY 206130
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4675 mL | 17.3376 mL | 34.6753 mL | |
| 5 mM | 0.6935 mL | 3.4675 mL | 6.9351 mL | |
| 10 mM | 0.3468 mL | 1.7338 mL | 3.4675 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.